{"fetched":"2026-10-28","previousFetched":"2026-10-21","window":{"from":"2026-06-30","to":"2026-10-28"},"sources":{"oce":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","drugsfda":"https://api.fda.gov/drug/drugsfda.json"},"oce":[{"date":"2026-10-26","title":"FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive","summary":"On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test.","drugIds":["enzalutamide","talazoparib"],"cancerIds":["prostate"],"firstSeen":"2026-10-28"},{"date":"2026-10-16","title":"FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph","summary":"On October 16, 2026, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.","drugIds":["pembrolizumab"],"cancerIds":[],"firstSeen":"2026-10-28"},{"date":"2026-10-19","title":"FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer","summary":"On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test for solid tumors.","drugIds":["dostarlimab"],"cancerIds":["rectal-cancer","colorectal"],"firstSeen":"2026-10-21"},{"date":"2026-10-14","title":"FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle","summary":"On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors to include patients with high-grade papillary-only tumors.","drugIds":["nogapendekin-alfa"],"cancerIds":["urothelial","non-muscle-invasive-bladder-cancer"],"firstSeen":"2026-10-21"},{"date":"2026-10-08","title":"FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer","summary":"On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.","drugIds":["atezolizumab","oxaliplatin"],"cancerIds":["colon-cancer"],"firstSeen":"2026-10-21"},{"date":"2026-10-07","title":"FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer","summary":"On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.","drugIds":["trastuzumab","pertuzumab","tucatinib"],"cancerIds":["breast-her2-positive","breast-cancer"],"firstSeen":"2026-10-21"},{"date":"2026-10-02","title":"FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic","summary":"On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.","drugIds":["pirtobrutinib"],"cancerIds":["non-hodgkin-lymphoma","adult-t-cell-leukaemia-lymphoma","leukaemia"],"firstSeen":"2026-10-07"},{"date":"2026-09-24","title":"FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-combination-lenvatinib-advanced-renal-cell-carcinoma-clear-cell-component","summary":"On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.","drugIds":["lenvatinib","belzutifan"],"cancerIds":["rcc","clear-cell-rcc"],"firstSeen":"2026-09-30"},{"date":"2026-09-23","title":"FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic","summary":"On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.","drugIds":["lirafugratinib"],"cancerIds":[],"firstSeen":"2026-09-30"},{"date":"2026-09-18","title":"FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-imlunestrant-combination-abemaciclib-er-positive-her2-negative-esr1-mutated-advanced-or","summary":"On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.","drugIds":["imlunestrant","abemaciclib"],"cancerIds":["breast-hr-positive","breast-cancer"],"firstSeen":"2026-09-23"},{"date":"2026-09-09","title":"FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sevabertinib-locally-advanced-or-metastatic-non-squamous-non-small","summary":"On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.","drugIds":["sevabertinib"],"cancerIds":["lung-cancer","lung-squamous-cell-carcinoma","nsclc"],"firstSeen":"2026-09-09"},{"date":"2026-09-04","title":"FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-camizestrant-cdk46-inhibitor-esr1-mutated-hr-positive-her2-negative","summary":"On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.","drugIds":["camizestrant","palbociclib","abemaciclib","ribociclib"],"cancerIds":["breast-cancer","breast-hr-positive"],"firstSeen":"2026-09-09"},{"date":"2026-08-26","title":"FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma","summary":"On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.","drugIds":["daraxonrasib"],"cancerIds":["pancreatic","urethral-adenocarcinoma","lung-adenocarcinoma"],"firstSeen":"2026-09-09"},{"date":"2026-08-25","title":"FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction","summary":"On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir","drugIds":["tislelizumab","zanidatamab","platinum-etoposide"],"cancerIds":["oesophageal-adenocarcinoma","urethral-adenocarcinoma","lung-adenocarcinoma","gastric"],"firstSeen":"2026-09-09"},{"date":"2026-08-13","title":"FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone","summary":"On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.","drugIds":["dexamethasone","daratumumab","iberdomide"],"cancerIds":["multiple-myeloma"],"firstSeen":"2026-09-09"},{"date":"2026-08-06","title":"FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma","summary":"On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.","drugIds":["vusolimogene-oderparepvec","nivolumab","relatlimab-nivolumab"],"cancerIds":["melanoma"],"firstSeen":"2026-09-09"},{"date":"2026-07-31","title":"FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy","summary":"On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).","drugIds":["pluvicto"],"cancerIds":["prostate-mhspc","prostate"],"firstSeen":"2026-09-09"},{"date":"2026-07-22","title":"FDA approves zidesamtinib for ROS1 -positive non-small cell lung cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer","summary":"On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).","drugIds":["zidesamtinib"],"cancerIds":["lung-cancer","nsclc"],"firstSeen":"2026-09-09"},{"date":"2026-07-14","title":"FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally","summary":"On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.","drugIds":["fulvestrant","palbociclib","gedatolisib"],"cancerIds":["breast-cancer","breast-hr-positive"],"firstSeen":"2026-09-09"},{"date":"2026-07-14","title":"FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive","summary":"On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.","drugIds":["selpercatinib"],"cancerIds":[],"firstSeen":"2026-09-09"},{"date":"2026-07-10","title":"FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin","summary":"On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.","drugIds":["enfortumab-vedotin","pembrolizumab","gemcitabine-cisplatin","cisplatin"],"cancerIds":["urothelial","muscle-invasive-bladder-cancer"],"firstSeen":"2026-09-09"},{"date":"2026-07-09","title":"FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-subcutaneous-injection-multiple-myeloma-indications","summary":"On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.","drugIds":["isatuximab"],"cancerIds":["multiple-myeloma"],"firstSeen":"2026-09-09"},{"date":"2026-06-30","title":"FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-allogeneic-regulatory-t-cell-based-immunotherapy-hspc-and-t-cells-vldq-use-matched","summary":"On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.","drugIds":["tregzi"],"cancerIds":[],"firstSeen":"2026-09-23"}],"drugsfda":[{"applicationNumber":"BLA761108","sponsor":"ALEXION PHARM","brand":"ULTOMIRIS","generic":"RAVULIZUMAB","submissionType":"SUPPL","submissionNumber":"46","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-23","drugIds":["ravulizumab"],"firstSeen":"2026-10-28"},{"applicationNumber":"BLA761136","sponsor":"CELGENE CORP","brand":"REBLOZYL","generic":"LUSPATERCEPT","submissionType":"SUPPL","submissionNumber":"17","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-20","drugIds":["luspatercept"],"firstSeen":"2026-10-28"},{"applicationNumber":"BLA761174","sponsor":"GLAXOSMITHKLINE","brand":"JEMPERLI","generic":"DOSTARLIMAB-GXLY","submissionType":"SUPPL","submissionNumber":"15","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-19","drugIds":["dostarlimab"],"firstSeen":"2026-10-28"},{"applicationNumber":"ANDA220407","sponsor":"ZYDUS PHARMS","brand":"ESTRADIOL AND LEVONORGESTREL","generic":"ESTRADIOL / LEVONORGESTREL","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-10-19","drugIds":["megestrol-progestins"],"firstSeen":"2026-10-28"},{"applicationNumber":"ANDA220783","sponsor":"ZYDUS PHARMS","brand":"ROMIDEPSIN","generic":"ROMIDEPSIN","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-10-19","drugIds":["romidepsin"],"firstSeen":"2026-10-28"},{"applicationNumber":"ANDA218930","sponsor":"KINDOS","brand":"ERIBULIN MESYLATE","generic":"ERIBULIN MESYLATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-10-19","drugIds":["eribulin"],"firstSeen":"2026-10-28"},{"applicationNumber":"NDA219097","sponsor":"SHORLA ONCOLOGY","brand":"IMKELDI","generic":"IMATINIB MESYLATE","submissionType":"SUPPL","submissionNumber":"4","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-16","drugIds":["imatinib"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA216099","sponsor":"HANDA THERAP","brand":"PHYRAGO","generic":"DASATINIB","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-16","drugIds":["dasatinib"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA217870","sponsor":"CIPLA","brand":"CABOZANTINIB S-MALATE","generic":"CABOZANTINIB S-MALATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-10-16","drugIds":["cabozantinib"],"firstSeen":"2026-10-28"},{"applicationNumber":"NDA212608","sponsor":"BLUEPRINT MEDICINES","brand":"AYVAKIT","generic":"AVAPRITINIB","submissionType":"SUPPL","submissionNumber":"21","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-16","drugIds":["avapritinib"],"firstSeen":"2026-10-28"},{"applicationNumber":"ANDA219922","sponsor":"TORRENT","brand":"PAZOPANIB HYDROCHLORIDE","generic":"PAZOPANIB HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-16","drugIds":["pazopanib"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA021986","sponsor":"BRISTOL MYERS SQUIBB","brand":"SPRYCEL","generic":"DASATINIB","submissionType":"SUPPL","submissionNumber":"29","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-16","drugIds":["dasatinib"],"firstSeen":"2026-10-21"},{"applicationNumber":"BLA761467","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA QLEX","generic":"PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH","submissionType":"SUPPL","submissionNumber":"8","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-16","drugIds":["pembrolizumab"],"firstSeen":"2026-10-21"},{"applicationNumber":"BLA125514","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA","generic":"PEMBROLIZUMAB","submissionType":"SUPPL","submissionNumber":"191","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-16","drugIds":["pembrolizumab"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA217723","sponsor":"ALEMBIC","brand":"CIPROFLOXACIN AND DEXAMETHASONE","generic":"CIPROFLOXACIN / DEXAMETHASONE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-10-15","drugIds":["dexamethasone"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA011719","sponsor":"HOSPIRA","brand":"METHOTREXATE PRESERVATIVE FREE","generic":"METHOTREXATE","submissionType":"SUPPL","submissionNumber":"144","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-15","drugIds":["methotrexate"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA214121","sponsor":"ACCORD HLTHCARE","brand":"METHOTREXATE","generic":"METHOTREXATE","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-15","drugIds":["methotrexate"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA218200","sponsor":"GLAND","brand":"LEUCOVORIN CALCIUM","generic":"LEUCOVORIN CALCIUM","submissionType":"SUPPL","submissionNumber":"1","classCode":"MANUF (CMC)","classDescription":"Manufacturing (CMC)","statusDate":"2026-10-14","drugIds":["leucovorin"],"firstSeen":"2026-10-21"},{"applicationNumber":"BLA761336","sponsor":"ALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SU","brand":"ANKTIVA","generic":"NOGAPENDEKIN ALFA INBAKICEPT-PMLN","submissionType":"SUPPL","submissionNumber":"2","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-14","drugIds":["nogapendekin-alfa"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA206775","sponsor":"ACCORD HLTHCARE","brand":"CARBOPLATIN","generic":"CARBOPLATIN","submissionType":"SUPPL","submissionNumber":"14","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-14","drugIds":["carboplatin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA208359","sponsor":"STRIDES PHARMA INTL","brand":"MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE","generic":"DONEPEZIL HYDROCHLORIDE / MEMANTINE HYDROCHLORIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-10-13","drugIds":["memantine"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA206846","sponsor":"ACCORD HLTHCARE","brand":"ONDANSETRON HYDROCHLORIDE","generic":"ONDANSETRON","submissionType":"SUPPL","submissionNumber":"12","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-13","drugIds":["ondansetron"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA206846","sponsor":"ACCORD HLTHCARE","brand":"ONDANSETRON HYDROCHLORIDE","generic":"ONDANSETRON","submissionType":"SUPPL","submissionNumber":"10","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-13","drugIds":["ondansetron"],"firstSeen":"2026-10-21"},{"applicationNumber":"BLA761347","sponsor":"GENENTECH INC","brand":"TECENTRIQ HYBREZA","generic":"ATEZOLIZUMAB AND HYALURONIDASE-TQJS","submissionType":"SUPPL","submissionNumber":"11","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-08","drugIds":["atezolizumab"],"firstSeen":"2026-10-21"},{"applicationNumber":"BLA761034","sponsor":"GENENTECH INC","brand":"TECENTRIQ","generic":"ATEZOLIZUMAB","submissionType":"SUPPL","submissionNumber":"65","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-08","drugIds":["atezolizumab"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA213571","sponsor":"UPSHER SMITH LABS","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"19","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA216097","sponsor":"AMNEAL PHARMS NY","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"3","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA076356","sponsor":"TEVA PHARMS USA","brand":"CLARAVIS","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"64","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA076135","sponsor":"TEVA PHARMS USA","brand":"CLARAVIS","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"70","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA211568","sponsor":"ZYDUS PHARMS","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"9","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA216633","sponsor":"ZYDUS PHARMS","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"4","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA211913","sponsor":"SUN PHARM","brand":"ABSORICA LD","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"24","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA220336","sponsor":"AUROBINDO PHARMA LTD","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"1","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA218194","sponsor":"AUROBINDO PHARMA","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"6","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA213411","sponsor":"SEAGEN","brand":"TUKYSA","generic":"TUCATINIB","submissionType":"SUPPL","submissionNumber":"10","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-07","drugIds":["tucatinib"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA212333","sponsor":"UPSHER SMITH LABS","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"20","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA207792","sponsor":"AMNEAL PHARMS NY","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"38","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA202099","sponsor":"DR REDDYS LABS LTD","brand":"ZENATANE","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"43","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA021951","sponsor":"SUN PHARM INDS INC","brand":"ABSORICA","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"32","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA205063","sponsor":"ACTAVIS LABS FL","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"13","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA075945","sponsor":"MYLAN PHARMS INC","brand":"AMNESTEEM","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"53","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA076485","sponsor":"UPSHER SMITH LABS","brand":"MYORISAN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"49","classCode":"REMS","classDescription":"REMS","statusDate":"2026-10-07","drugIds":["isotretinoin"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA017453","sponsor":"TEVA BRANDED PHARM","brand":"PROGLYCEM","generic":"DIAZOXIDE","submissionType":"SUPPL","submissionNumber":"25","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-06","drugIds":["diazoxide"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA216059","sponsor":"LOXO ONCOL","brand":"JAYPIRCA","generic":"PIRTOBRUTINIB","submissionType":"SUPPL","submissionNumber":"6","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-10-02","drugIds":["pirtobrutinib"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA213301","sponsor":"UNICHEM","brand":"CELECOXIB","generic":"CELECOXIB","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-02","drugIds":["celecoxib"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA211860","sponsor":"BAXTER HLTHCARE CORP","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT DIMEGLUMINE","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-02","drugIds":["aprepitant"],"firstSeen":"2026-10-07"},{"applicationNumber":"NDA020802","sponsor":"HALEON US HOLDINGS","brand":"EXCEDRIN (MIGRAINE RELIEF)","generic":"ACETAMINOPHEN, ASPRIN, CAFFEINE","submissionType":"SUPPL","submissionNumber":"46","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-02","drugIds":["aspirin"],"firstSeen":"2026-10-07"},{"applicationNumber":"NDA219617","sponsor":"EVER","brand":"TRABECTEDIN","generic":"TRABECTEDIN","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 5","classDescription":"Type 5 - New Formulation or New Manufacturer","statusDate":"2026-10-01","drugIds":["trabectedin"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA210762","sponsor":"FRESENIUS KABI USA","brand":"FENTANYL CITRATE PRESERVATIVE FREE","generic":"FENTANYL CITRATE","submissionType":"SUPPL","submissionNumber":"10","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-01","drugIds":["fentanyl"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA210762","sponsor":"FRESENIUS KABI USA","brand":"FENTANYL CITRATE PRESERVATIVE FREE","generic":"FENTANYL CITRATE","submissionType":"SUPPL","submissionNumber":"11","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-01","drugIds":["fentanyl"],"firstSeen":"2026-10-21"},{"applicationNumber":"NDA212725","sponsor":"GENENTECH INC","brand":"ROZLYTREK","generic":"ENTRECTINIB","submissionType":"SUPPL","submissionNumber":"14","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-01","drugIds":["entrectinib"],"firstSeen":"2026-10-07"},{"applicationNumber":"NDA218550","sponsor":"GENENTECH INC","brand":"ROZLYTREK","generic":"ENTRECTINIB","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-10-01","drugIds":["entrectinib"],"firstSeen":"2026-10-07"},{"applicationNumber":"NDA016785","sponsor":"LEADIANT BIOSCI INC","brand":"MATULANE","generic":"PROCARBAZINE HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"44","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-30","drugIds":["procarbazine"],"firstSeen":"2026-10-07"},{"applicationNumber":"NDA213702","sponsor":"JAZZ","brand":"ZEPZELCA","generic":"LURBINECTEDIN","submissionType":"SUPPL","submissionNumber":"13","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-30","drugIds":["lurbinectedin"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA040263","sponsor":"FRESENIUS KABI USA","brand":"METHOTREXATE SODIUM","generic":"METHOTREXATE SODIUM","submissionType":"SUPPL","submissionNumber":"24","classCode":"MANUF (CMC)","classDescription":"Manufacturing (CMC)","statusDate":"2026-09-30","drugIds":["methotrexate"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA210628","sponsor":"PHARMAZONE","brand":"CELECOXIB","generic":"CELECOXIB","submissionType":"SUPPL","submissionNumber":"18","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-30","drugIds":["celecoxib"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA210071","sponsor":"CSPC OUYI","brand":"CELECOXIB","generic":"CELECOXIB","submissionType":"SUPPL","submissionNumber":"5","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-29","drugIds":["celecoxib"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA761140","sponsor":"AMGEN INC","brand":"RIABNI","generic":"RITUXIMAB-ARRX","submissionType":"SUPPL","submissionNumber":"5","classCode":"BIOEQUIV","classDescription":"Bioequivalence","statusDate":"2026-09-29","drugIds":["rituximab"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA761377","sponsor":"CELLTRION INC","brand":"EYDENZELT","generic":"AFLIBERCEPT-BOAV","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-29","drugIds":["ziv-aflibercept"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA761385","sponsor":"TEVA PHARMACEUTICALS, INC.","brand":"PONLIMSI","generic":"DENOSUMAB-ADET","submissionType":"SUPPL","submissionNumber":"6","classCode":"BIOSIMILAR","statusDate":"2026-09-29","drugIds":["denosumab"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA761420","sponsor":"CELLTRION INC","brand":"AVTOZMA","generic":"TOCILIZUMAB-ANOH","submissionType":"SUPPL","submissionNumber":"8","classCode":"BIOSIMILAR","statusDate":"2026-09-29","drugIds":["tocilizumab"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA761498","sponsor":"CELLTRION INC","brand":"AVTOZMA","generic":"TOCILIZUMAB-ANOH","submissionType":"SUPPL","submissionNumber":"3","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-29","drugIds":["tocilizumab"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA761103","sponsor":"PFIZER INC","brand":"RUXIENCE","generic":"RITUXIMAB-PVVR","submissionType":"SUPPL","submissionNumber":"20","classCode":"BIOSIMILAR","statusDate":"2026-09-28","drugIds":["rituximab"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA212778","sponsor":"UPSHER SMITH LABS","brand":"PREDNISOLONE ACETATE","generic":"PREDNISOLONE ACETATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-28","drugIds":["prednisone"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA078035","sponsor":"ACTAVIS LABS FL INC","brand":"CABERGOLINE","generic":"CABERGOLINE","submissionType":"SUPPL","submissionNumber":"12","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-25","drugIds":["cabergoline"],"firstSeen":"2026-10-21"},{"applicationNumber":"ANDA090943","sponsor":"RISING","brand":"CAPECITABINE","generic":"CAPECITABINE","submissionType":"SUPPL","submissionNumber":"16","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-25","drugIds":["capecitabine-temozolomide","capecitabine"],"firstSeen":"2026-10-07"},{"applicationNumber":"NDA219014","sponsor":"AVYXA HOLDINGS","brand":"GOBARDEN","generic":"BENDAMUSTINE HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-25","drugIds":["bendamustine"],"firstSeen":"2026-10-07"},{"applicationNumber":"BLA125486","sponsor":"GENENTECH","brand":"GAZYVA","generic":"OBINUTUZUMAB","submissionType":"SUPPL","submissionNumber":"43","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-25","drugIds":["obinutuzumab"],"firstSeen":"2026-09-30"},{"applicationNumber":"BLA761481","sponsor":"TEVA PHARMACEUTICALS, INC.","brand":"DEGEVMA","generic":"DENOSUMAB-ADET","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 5","classDescription":"Type 5 - New Formulation or New Manufacturer","statusDate":"2026-09-25","drugIds":["denosumab"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA209780","sponsor":"NEXUS","brand":"ARSENIC TRIOXIDE","generic":"ARSENIC TRIOXIDE","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-24","drugIds":["arsenic-trioxide"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA200144","sponsor":"RISING","brand":"IDARUBICIN HYDROCHLORIDE","generic":"IDARUBICIN HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"4","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-24","drugIds":["idarubicin"],"firstSeen":"2026-10-07"},{"applicationNumber":"ANDA200144","sponsor":"RISING","brand":"IDARUBICIN HYDROCHLORIDE","generic":"IDARUBICIN HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"5","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-24","drugIds":["idarubicin"],"firstSeen":"2026-10-07"},{"applicationNumber":"NDA206947","sponsor":"EISAI INC","brand":"LENVIMA","generic":"LENVATINIB MESYLATE","submissionType":"SUPPL","submissionNumber":"35","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-24","drugIds":["lenvatinib"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA215383","sponsor":"MERCK SHARP DOHME","brand":"WELIREG","generic":"BELZUTIFAN","submissionType":"SUPPL","submissionNumber":"17","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-24","drugIds":["belzutifan"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA215383","sponsor":"MERCK SHARP DOHME","brand":"WELIREG","generic":"BELZUTIFAN","submissionType":"SUPPL","submissionNumber":"13","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-24","drugIds":["belzutifan"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA220425","sponsor":"ELEVAR","brand":"LYRFIGTU","generic":"LIRAFUGRATINIB HYDROCHLORIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-09-23","drugIds":["lirafugratinib"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA212099","sponsor":"BAYER HEALTHCARE","brand":"NUBEQA","generic":"DAROLUTAMIDE","submissionType":"SUPPL","submissionNumber":"16","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-22","drugIds":["darolutamide"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA215358","sponsor":"NOVARTIS","brand":"SCEMBLIX","generic":"ASCIMINIB HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"15","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-22","drugIds":["asciminib"],"firstSeen":"2026-09-30"},{"applicationNumber":"ANDA206801","sponsor":"FRESENIUS KABI USA","brand":"PALONOSETRON HYDROCHLORIDE","generic":"PALONOSETRON","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-21","drugIds":["palonosetron"],"firstSeen":"2026-09-30"},{"applicationNumber":"ANDA206802","sponsor":"FRESENIUS KABI USA","brand":"PALONOSETRON HYDROCHLORIDE","generic":"PALONOSETRON","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-21","drugIds":["palonosetron"],"firstSeen":"2026-09-30"},{"applicationNumber":"ANDA220597","sponsor":"NOVITIUM PHARMA","brand":"EVEROLIMUS","generic":"EVEROLIMUS","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-21","drugIds":["everolimus"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA208716","sponsor":"ELI LILLY AND CO","brand":"VERZENIO","generic":"ABEMACICLIB","submissionType":"SUPPL","submissionNumber":"22","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-18","drugIds":["abemaciclib"],"firstSeen":"2026-09-30"},{"applicationNumber":"ANDA218217","sponsor":"AMNEAL","brand":"LANREOTIDE ACETATE","generic":"LANREOTIDE ACETATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-18","drugIds":["octreotide-lanreotide"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA218881","sponsor":"ELI LILLY AND CO","brand":"INLURIYO","generic":"IMLUNESTRANT TOSYLATE","submissionType":"SUPPL","submissionNumber":"1","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-18","drugIds":["imlunestrant"],"firstSeen":"2026-09-30"},{"applicationNumber":"ANDA090713","sponsor":"TEVA PHARMS USA","brand":"PALONOSETRON HYDROCHLORIDE","generic":"PALONOSETRON HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"3","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-17","drugIds":["palonosetron"],"firstSeen":"2026-09-30"},{"applicationNumber":"ANDA079179","sponsor":"APOTEX","brand":"IMATINIB MESYLATE","generic":"IMATINIB MESYLATE","submissionType":"SUPPL","submissionNumber":"24","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-17","drugIds":["imatinib"],"firstSeen":"2026-09-30"},{"applicationNumber":"ANDA079179","sponsor":"APOTEX","brand":"IMATINIB MESYLATE","generic":"IMATINIB MESYLATE","submissionType":"SUPPL","submissionNumber":"22","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-17","drugIds":["imatinib"],"firstSeen":"2026-09-30"},{"applicationNumber":"NDA218197","sponsor":"ASTRAZENECA","brand":"TRUQAP","generic":"CAPIVASERTIB","submissionType":"SUPPL","submissionNumber":"6","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-16","drugIds":["capivasertib"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA219713","sponsor":"NUVATION","brand":"IBTROZI","generic":"TALETRECTINIB ADIPATE","submissionType":"SUPPL","submissionNumber":"4","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-16","drugIds":["taletrectinib"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA021560","sponsor":"NOVARTIS","brand":"ZORTRESS","generic":"EVEROLIMUS","submissionType":"SUPPL","submissionNumber":"34","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-16","drugIds":["everolimus"],"firstSeen":"2026-09-30"},{"applicationNumber":"ANDA090292","sponsor":"ACTAVIS TOTOWA","brand":"LETROZOLE","generic":"LETROZOLE","submissionType":"SUPPL","submissionNumber":"1","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-15","drugIds":["letrozole"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA075945","sponsor":"MYLAN PHARMS INC","brand":"AMNESTEEM","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"45","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-15","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA218560","sponsor":"ZYDUS LIFESCIENCES","brand":"TRETINOIN","generic":"TRETINOIN","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-15","drugIds":["tretinoin-atra"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA220438","sponsor":"ZYDUS LIFESCIENCES","brand":"LETROZOLE","generic":"LETROZOLE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-14","drugIds":["letrozole"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA208065","sponsor":"ASTRAZENECA","brand":"TAGRISSO","generic":"OSIMERTINIB MESYLATE","submissionType":"SUPPL","submissionNumber":"36","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-14","drugIds":["osimertinib"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA208065","sponsor":"ASTRAZENECA","brand":"TAGRISSO","generic":"OSIMERTINIB MESYLATE","submissionType":"SUPPL","submissionNumber":"35","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-14","drugIds":["osimertinib"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA219579","sponsor":"MSN","brand":"DASATINIB","generic":"DASATINIB","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-11","drugIds":["dasatinib"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA075184","sponsor":"TEVA PHARMS","brand":"PACLITAXEL","generic":"PACLITAXEL","submissionType":"SUPPL","submissionNumber":"22","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-11","drugIds":["paclitaxel"],"firstSeen":"2026-09-23"},{"applicationNumber":"BLA761344","sponsor":"AMGEN INC","brand":"IMDELLTRA","generic":"TARLATAMAB-DLLE","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-11","drugIds":["tarlatamab"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA203554","sponsor":"RISING","brand":"PENTOSTATIN","generic":"PENTOSTATIN","submissionType":"SUPPL","submissionNumber":"3","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-11","drugIds":["pentostatin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA220336","sponsor":"AUROBINDO PHARMA LTD","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-10","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA208081","sponsor":"BIOFRONTERA","brand":"AMELUZ","generic":"AMINOLEVULINIC ACID HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"40","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-09","drugIds":["aminolevulinic-acid"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA219972","sponsor":"BAYER HEALTHCARE","brand":"HYRNUO","generic":"SEVABERTINIB","submissionType":"SUPPL","submissionNumber":"1","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-09-09","drugIds":["sevabertinib"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA211182","sponsor":"HETERO LABS LTD V","brand":"IBRUTINIB","generic":"IBRUTINIB","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-08","drugIds":["ibrutinib"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA220359","sponsor":"ASTRAZENECA","brand":"ETCAMAH","generic":"CAMIZESTRANT","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-09-04","drugIds":["camizestrant"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA220613","sponsor":"HANDA ONCOL","brand":"OMCAZIO","generic":"CABOZANTINIB LAURYLSULFATE","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 5","classDescription":"Type 5 - New Formulation or New Manufacturer","statusDate":"2026-09-03","drugIds":["cabozantinib"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA020785","sponsor":"BRISTOL-MYERS","brand":"THALOMID","generic":"THALIDOMIDE","submissionType":"SUPPL","submissionNumber":"74","classCode":"REMS","classDescription":"REMS","statusDate":"2026-09-02","drugIds":["thalidomide"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA213267","sponsor":"NATCO","brand":"THALIDOMIDE","generic":"THALIDOMIDE","submissionType":"SUPPL","submissionNumber":"2","classCode":"REMS","classDescription":"REMS","statusDate":"2026-09-02","drugIds":["thalidomide"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA213312","sponsor":"AADI","brand":"FYARRO","generic":"SIROLIMUS","submissionType":"SUPPL","submissionNumber":"14","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-02","drugIds":["sirolimus","sirolimus-albumin-bound"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA210245","sponsor":"MSN","brand":"POMALIDOMIDE","generic":"POMALIDOMIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-09-02","drugIds":["pomalidomide"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA020457","sponsor":"CHEPLAPHARM","brand":"ETOPOPHOS PRESERVATIVE FREE","generic":"ETOPOSIDE PHOSPHATE","submissionType":"SUPPL","submissionNumber":"20","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-02","drugIds":["platinum-etoposide","etoposide"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761420","sponsor":"CELLTRION INC","brand":"AVTOZMA","generic":"TOCILIZUMAB-ANOH","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-02","drugIds":["tocilizumab"],"firstSeen":"2026-09-16"},{"applicationNumber":"BLA761498","sponsor":"CELLTRION INC","brand":"AVTOZMA","generic":"TOCILIZUMAB-ANOH","submissionType":"SUPPL","submissionNumber":"1","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-02","drugIds":["tocilizumab"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA216038","sponsor":"MEITHEAL","brand":"NELARABINE","generic":"NELARABINE","submissionType":"SUPPL","submissionNumber":"4","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-01","drugIds":["nelarabine"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA216340","sponsor":"BRISTOL","brand":"KRAZATI","generic":"ADAGRASIB","submissionType":"SUPPL","submissionNumber":"11","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-09-01","drugIds":["adagrasib"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761097","sponsor":"REGENERON PHARMACEUTICALS","brand":"LIBTAYO","generic":"CEMIPLIMAB-RWLC","submissionType":"SUPPL","submissionNumber":"38","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["cemiplimab"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA213234","sponsor":"DR REDDYS","brand":"POMALIDOMIDE","generic":"POMALIDOMIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-31","drugIds":["pomalidomide"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA219718","sponsor":"CIPLA","brand":"POMALIDOMIDE","generic":"POMALIDOMIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-31","drugIds":["pomalidomide"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761240","sponsor":"COHERUS BIOSCIENCES INC","brand":"LOQTORZI","generic":"TORIPALIMAB-TPZI","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["toripalimab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761258","sponsor":"AKESO BIOPHARMA","brand":"PENPULIMAB-KCQX","generic":"PENPULIMAB","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["penpulimab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761289","sponsor":"ASTRAZENECA AB","brand":"IMJUDO","generic":"TREMELIMUMAB","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["tremelimumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761297","sponsor":"CHECKPOINT THERAPEUTICS INC","brand":"UNLOXCYT","generic":"COSIBELIMAB-IPDL","submissionType":"SUPPL","submissionNumber":"4","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["cosibelimab"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA220741","sponsor":"SANDOZ","brand":"POMALIDOMIDE","generic":"POMALIDOMIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-31","drugIds":["pomalidomide"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA079086","sponsor":"PETNET","brand":"FLUDEOXYGLUCOSE F18","generic":"FLUDEOXYGLUCOSE F 18","submissionType":"SUPPL","submissionNumber":"31","classCode":"MANUF (CMC)","classDescription":"Manufacturing (CMC)","statusDate":"2026-08-31","drugIds":["fludeoxyglucose-f18"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA210232","sponsor":"SPIL","brand":"POMALIDOMIDE","generic":"POMALIDOMIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-31","drugIds":["pomalidomide"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA125377","sponsor":"BRISTOL MYERS SQUIBB","brand":"YERVOY","generic":"IPILIMUMAB","submissionType":"SUPPL","submissionNumber":"140","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["ipilimumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761049","sponsor":"EMD SERONO INC","brand":"BAVENCIO","generic":"AVELUMAB","submissionType":"SUPPL","submissionNumber":"26","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["avelumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761069","sponsor":"ASTRAZENECA UK LTD","brand":"IMFINZI","generic":"DURVALUMAB","submissionType":"SUPPL","submissionNumber":"60","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-31","drugIds":["durvalumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761166","sponsor":"PHARMAESSENTIA CORP","brand":"BESREMI","generic":"ROPEGINTERFERON ALFA-2B","submissionType":"SUPPL","submissionNumber":"13","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-08-28","drugIds":["ropeginterferon-alfa-2b"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA220605","sponsor":"TAKEDA PHARMS AM","brand":"MIMRYLO","generic":"RUSFERTIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-08-28","drugIds":["rusfertide"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA205410","sponsor":"ETON","brand":"HEMANGEOL","generic":"PROPRANOLOL HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"7","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-28","drugIds":["propranolol-hemangeol"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA213225","sponsor":"SUN PHARM","brand":"VOBRIG","generic":"LEUPROLIDE ACETATE","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 5","classDescription":"Type 5 - New Formulation or New Manufacturer","statusDate":"2026-08-26","drugIds":["leuprolide","goserelin"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA220910","sponsor":"REVOLUTION MEDICINES","brand":"RASONQUE","generic":"DARAXONRASIB","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-08-26","drugIds":["daraxonrasib"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761232","sponsor":"BEIGENE","brand":"TEVIMBRA","generic":"TISLELIZUMAB-JSGR","submissionType":"SUPPL","submissionNumber":"18","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-08-25","drugIds":["tislelizumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761416","sponsor":"JAZZ PHARMS","brand":"ZIIHERA","generic":"ZANIDATAMAB-HRII","submissionType":"SUPPL","submissionNumber":"2","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-08-25","drugIds":["zanidatamab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761416","sponsor":"JAZZ PHARMS","brand":"ZIIHERA","generic":"ZANIDATAMAB-HRII","submissionType":"SUPPL","submissionNumber":"3","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-25","drugIds":["zanidatamab"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA076356","sponsor":"TEVA PHARMS USA","brand":"CLARAVIS","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"63","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-21","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA076135","sponsor":"TEVA PHARMS USA","brand":"CLARAVIS","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"69","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-21","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA211568","sponsor":"ZYDUS PHARMS","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"8","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-21","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA207792","sponsor":"AMNEAL PHARMS NY","brand":"ISOTRETINOIN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"36","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-21","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA202099","sponsor":"DR REDDYS LABS LTD","brand":"ZENATANE","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"44","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-21","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA075945","sponsor":"MYLAN PHARMS INC","brand":"AMNESTEEM","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"54","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-21","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA076485","sponsor":"UPSHER SMITH LABS","brand":"MYORISAN","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"51","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-21","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"BLA761274","sponsor":"BIOCON BIOLOGICS INC","brand":"YESAFILI","generic":"AFLIBERCEPT-JBVF","submissionType":"SUPPL","submissionNumber":"8","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-20","drugIds":["ziv-aflibercept"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA206192","sponsor":"GENENTECH INC","brand":"COTELLIC","generic":"COBIMETINIB","submissionType":"SUPPL","submissionNumber":"7","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-20","drugIds":["cobimetinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA202429","sponsor":"HOFFMANN LA ROCHE","brand":"ZELBORAF","generic":"VEMURAFENIB","submissionType":"SUPPL","submissionNumber":"23","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-20","drugIds":["vemurafenib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA217677","sponsor":"SPRINGWORKS","brand":"OGSIVEO","generic":"NIROGACESTAT","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-20","drugIds":["nirogacestat"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA213106","sponsor":"QILU PHARM HAINAN","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT DIMEGLUMINE","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-19","drugIds":["aprepitant"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA220118","sponsor":"BIOCON PHARMA","brand":"NINTEDANIB ESYLATE","generic":"NINTEDANIB ESYLATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-19","drugIds":["nintedanib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA208434","sponsor":"HOFFMANN-LA ROCHE","brand":"ALECENSA","generic":"ALECTINIB HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"17","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-14","drugIds":["alectinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA219460","sponsor":"CREEKWOOD PHARMS","brand":"PROPRANOLOL HYDROCHLORIDE","generic":"PROPRANOLOL HYDROCHLORIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-14","drugIds":["propranolol-hemangeol"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA213878","sponsor":"MSN","brand":"CABOZANTINIB S-MALATE","generic":"CABOZANTINIB S-MALATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-14","drugIds":["cabozantinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA221075","sponsor":"BRISTOL MYERS SQUIBB","brand":"ZENBEXUS","generic":"IBERDOMIDE","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-08-13","drugIds":["iberdomide"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA201848","sponsor":"DELCATH SYSTEMS INC","brand":"HEPZATO","generic":"MELPHALAN HYDROCHLORIDE INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","submissionType":"SUPPL","submissionNumber":"18","classCode":"REMS","classDescription":"REMS","statusDate":"2026-08-12","drugIds":["hepzato","melphalan"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA125554","sponsor":"BRISTOL MYERS SQUIBB","brand":"OPDIVO","generic":"NIVOLUMAB","submissionType":"SUPPL","submissionNumber":"138","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-12","drugIds":["nivolumab","relatlimab-nivolumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA040266","sponsor":"FRESENIUS KABI USA","brand":"METHOTREXATE PRESERVATIVE FREE","generic":"METHOTREXATE SODIUM","submissionType":"SUPPL","submissionNumber":"23","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-11","drugIds":["methotrexate"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA211913","sponsor":"SUN PHARM","brand":"ABSORICA LD","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"23","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-11","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA021951","sponsor":"SUN PHARM INDS INC","brand":"ABSORICA","generic":"ISOTRETINOIN","submissionType":"SUPPL","submissionNumber":"31","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-11","drugIds":["isotretinoin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA206197","sponsor":"FRESENIUS KABI USA","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-07","drugIds":["aprepitant"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA212309","sponsor":"BE PHARMS","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT","submissionType":"SUPPL","submissionNumber":"18","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-07","drugIds":["aprepitant"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA210625","sponsor":"EUGIA PHARMA","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT DIMEGLUMINE","submissionType":"SUPPL","submissionNumber":"8","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-07","drugIds":["aprepitant"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA209965","sponsor":"MSN","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-07","drugIds":["aprepitant"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA209965","sponsor":"MSN","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT","submissionType":"SUPPL","submissionNumber":"4","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-07","drugIds":["aprepitant"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA204015","sponsor":"MYLAN LABS LTD","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-07","drugIds":["aprepitant"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA207944","sponsor":"PH HEALTH","brand":"ASPIRIN AND DIPYRIDAMOLE","generic":"ASPIRIN AND EXTENDED - RELEASE DIPYRIDAMOLE","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-05","drugIds":["aspirin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA207944","sponsor":"PH HEALTH","brand":"ASPIRIN AND DIPYRIDAMOLE","generic":"ASPIRIN AND EXTENDED - RELEASE DIPYRIDAMOLE","submissionType":"SUPPL","submissionNumber":"5","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-05","drugIds":["aspirin"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA219199","sponsor":"ALEMBIC","brand":"DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)","generic":"DOXORUBICIN HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"4","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-04","drugIds":["doxorubicin"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA219881","sponsor":"QILU PHARM HAINAN","brand":"DOXORUBICIN HYDROCHLORIDE","generic":"DOXORUBICIN HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"1","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-04","drugIds":["doxorubicin"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA212299","sponsor":"ZYDUS LIFESCIENCES","brand":"DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)","generic":"DOXORUBICIN HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"17","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-04","drugIds":["doxorubicin"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA125031","sponsor":"AMGEN","brand":"NEULASTA","generic":"PEGFILGRASTIM","submissionType":"SUPPL","submissionNumber":"210","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-04","drugIds":["pegfilgrastim"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA203263","sponsor":"SUN PHARM","brand":"DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)","generic":"DOXORUBICIN HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"47","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-04","drugIds":["doxorubicin"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA072168","sponsor":"HOSPIRA","brand":"CYTARABINE","generic":"CYTARABINE","submissionType":"SUPPL","submissionNumber":"36","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-03","drugIds":["cytarabine-7-3","cytarabine"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA219926","sponsor":"MACLEODS PHARMS","brand":"NINTEDANIB ESYLATE","generic":"NINTEDANIB ESYLATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-08-03","drugIds":["nintedanib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA072945","sponsor":"HOSPIRA","brand":"CYTARABINE","generic":"CYTARABINE","submissionType":"SUPPL","submissionNumber":"31","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-03","drugIds":["cytarabine-7-3","cytarabine"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA075383","sponsor":"HOSPIRA","brand":"CYTARABINE","generic":"CYTARABINE","submissionType":"SUPPL","submissionNumber":"24","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-08-03","drugIds":["cytarabine-7-3","cytarabine"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA215833","sponsor":"NOVARTIS","brand":"PLUVICTO","generic":"LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN","submissionType":"SUPPL","submissionNumber":"37","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-31","drugIds":["pluvicto"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761376","sponsor":"DR REDDYS LABS SA","brand":"ZIMRIXBY","generic":"RITUXIMAB-CDXX","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-31","drugIds":["rituximab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761400","sponsor":"RENGENERON PHARMACEUTICALS, INC.","brand":"LYNOZYFIC","generic":"LINVOSELTAMAB-GCPT","submissionType":"SUPPL","submissionNumber":"3","classCode":"REMS","classDescription":"REMS","statusDate":"2026-07-31","drugIds":["linvoseltamab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761467","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA QLEX","generic":"PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH","submissionType":"SUPPL","submissionNumber":"15","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-31","drugIds":["pembrolizumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA219042","sponsor":"BOEHRINGER INGELHEIM","brand":"HERNEXEOS","generic":"ZONGERTINIB","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-31","drugIds":["zongertinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA219042","sponsor":"BOEHRINGER INGELHEIM","brand":"HERNEXEOS","generic":"ZONGERTINIB","submissionType":"SUPPL","submissionNumber":"5","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-31","drugIds":["zongertinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA217379","sponsor":"CYCLE","brand":"CAVHANZA","generic":"NILOTINIB","submissionType":"SUPPL","submissionNumber":"2","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-29","drugIds":["nilotinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA076972","sponsor":"FRESENIUS KABI USA","brand":"ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE","generic":"ONDANSETRON HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"19","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-29","drugIds":["ondansetron"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA076974","sponsor":"FRESENIUS KABI USA","brand":"ONDANSETRON HYDROCHLORIDE","generic":"ONDANSETRON HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"18","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-29","drugIds":["ondansetron"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA071868","sponsor":"HOSPIRA","brand":"CYTARABINE","generic":"CYTARABINE","submissionType":"SUPPL","submissionNumber":"38","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-29","drugIds":["cytarabine-7-3","cytarabine"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA203939","sponsor":"CAPLIN","brand":"FOSAPREPITANT DIMEGLUMINE","generic":"FOSAPREPITANT DIMEGLUMINE","submissionType":"SUPPL","submissionNumber":"4","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-28","drugIds":["aprepitant"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA203415","sponsor":"ASTELLAS","brand":"XTANDI","generic":"ENZALUTAMIDE","submissionType":"SUPPL","submissionNumber":"26","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-24","drugIds":["enzalutamide"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA213674","sponsor":"ASTELLAS","brand":"XTANDI","generic":"ENZALUTAMIDE","submissionType":"SUPPL","submissionNumber":"16","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-24","drugIds":["enzalutamide"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761320","sponsor":"OUTLOOK THERAPEUTICS, INC.","brand":"LYTENAVA","generic":"BEVACIZUMAB-VIKG","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1/4","classDescription":"Type 1 - New Molecular Entity and Type 4 - New Combination","statusDate":"2026-07-24","drugIds":["bevacizumab-glioma","bevacizumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA220196","sponsor":"HISUN PHARM HANGZHOU","brand":"FLUDARABINE PHOSPHATE","generic":"FLUDARABINE PHOSPHATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-23","drugIds":["fludarabine"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA021880","sponsor":"BRISTOL MYERS SQUIBB","brand":"REVLIMID","generic":"LENALIDOMIDE","submissionType":"SUPPL","submissionNumber":"70","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-22","drugIds":["lenalidomide"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA220185","sponsor":"NUVALENT","brand":"JIDEYTRO","generic":"ZIDESAMTINIB","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-07-22","drugIds":["zidesamtinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA219745","sponsor":"ACCORD","brand":"CAMCEVI ETM","generic":"LEUPROLIDE MESYLATE","submissionType":"SUPPL","submissionNumber":"1","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-21","drugIds":["goserelin","leuprolide"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA208712","sponsor":"SOBI","brand":"VONJO","generic":"PACRITINIB","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-20","drugIds":["pacritinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA216873","sponsor":"GLAXOSMITHKLINE","brand":"OJJAARA","generic":"MOMELOTINIB","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-20","drugIds":["momelotinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA209526","sponsor":"MSN","brand":"CARFILZOMIB","generic":"CARFILZOMIB","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-20","drugIds":["carfilzomib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA212327","sponsor":"BRISTOL-MYERS","brand":"INREBIC","generic":"FEDRATINIB HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"11","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-20","drugIds":["fedratinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA217180","sponsor":"INCYTE CORP","brand":"JAKAFI XR","generic":"RUXOLITINIB","submissionType":"SUPPL","submissionNumber":"1","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-20","drugIds":["ruxolitinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA202192","sponsor":"INCYTE CORP","brand":"JAKAFI","generic":"RUXOLITINIB","submissionType":"SUPPL","submissionNumber":"33","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-20","drugIds":["ruxolitinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA204519","sponsor":"ALEMBIC","brand":"CELECOXIB","generic":"CELECOXIB","submissionType":"SUPPL","submissionNumber":"25","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-17","drugIds":["celecoxib"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA204549","sponsor":"ACTAVIS INC","brand":"GEMCITABINE HYDROCHLORIDE","generic":"GEMCITABINE HYDROCHLORIDE","submissionType":"SUPPL","submissionNumber":"5","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-17","drugIds":["gemcitabine-nab-paclitaxel","gemcitabine-cisplatin","gemcitabine"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA209192","sponsor":"FRESENIUS KABI USA","brand":"DEXAMETHASONE SODIUM PHOSPHATE","generic":"DEXAMETHASONE SODIUM PHOSPHATE","submissionType":"SUPPL","submissionNumber":"5","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-17","drugIds":["dexamethasone"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA217677","sponsor":"SPRINGWORKS","brand":"OGSIVEO","generic":"NIROGACESTAT","submissionType":"SUPPL","submissionNumber":"8","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-17","drugIds":["nirogacestat"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA103353","sponsor":"AMGEN","brand":"NEUPOGEN","generic":"FILGRASTIM","submissionType":"SUPPL","submissionNumber":"5202","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-16","drugIds":["filgrastim"],"firstSeen":"2026-09-16"},{"applicationNumber":"NDA205919","sponsor":"NOVA LABS LTD","brand":"PURIXAN","generic":"MERCAPTOPURINE","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-16","drugIds":["mercaptopurine"],"firstSeen":"2026-09-16"},{"applicationNumber":"ANDA210725","sponsor":"APOTEX","brand":"AFATINIB DIMALEATE","generic":"AFATINIB DIMALEATE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-14","drugIds":["afatinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA218160","sponsor":"ELI LILLY AND CO","brand":"RETEVMO","generic":"SELPERCATINIB","submissionType":"SUPPL","submissionNumber":"7","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-14","drugIds":["selpercatinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA210750","sponsor":"HETERO LABS LTD V","brand":"AFATINIB DIMALEATE","generic":"AFATINIB","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-14","drugIds":["afatinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA213246","sponsor":"ELI LILLY AND CO","brand":"RETEVMO","generic":"SELPERCATINIB","submissionType":"SUPPL","submissionNumber":"17","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-14","drugIds":["selpercatinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA219908","sponsor":"CELCUITY","brand":"REVTORPYK","generic":"GEDATOLISIB","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 1","classDescription":"Type 1 - New Molecular Entity","statusDate":"2026-07-14","drugIds":["gedatolisib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA208716","sponsor":"ELI LILLY AND CO","brand":"VERZENIO","generic":"ABEMACICLIB","submissionType":"SUPPL","submissionNumber":"21","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-13","drugIds":["abemaciclib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA209938","sponsor":"TEVA PHARMS USA","brand":"ELTROMBOPAG OLAMINE","generic":"ELTROMBOPAG OLAMINE","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-13","drugIds":["eltrombopag"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA021588","sponsor":"NOVARTIS","brand":"GLEEVEC","generic":"IMATINIB MESYLATE","submissionType":"SUPPL","submissionNumber":"67","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-13","drugIds":["imatinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761137","sponsor":"ASTELLAS","brand":"PADCEV","generic":"ENFORTUMAB VEDOTIN","submissionType":"SUPPL","submissionNumber":"37","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-10","drugIds":["enfortumab-vedotin"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761467","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA QLEX","generic":"PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH","submissionType":"SUPPL","submissionNumber":"12","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-10","drugIds":["pembrolizumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA125514","sponsor":"MERCK SHARP DOHME","brand":"KEYTRUDA","generic":"PEMBROLIZUMAB","submissionType":"SUPPL","submissionNumber":"194","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-10","drugIds":["pembrolizumab"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA212555","sponsor":"GLENMARK PHARMS LTD","brand":"NINTEDANIB ESYLATE","generic":"NINTEDANIB","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-09","drugIds":["nintedanib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA218472","sponsor":"HUMANWELL PURACAP","brand":"NINTEDANIB ESYLATE","generic":"NINTEDANIB","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-07-09","drugIds":["nintedanib"],"firstSeen":"2026-09-09"},{"applicationNumber":"BLA761445","sponsor":"SANOFI-AVENTIS U.S. LLC","brand":"SARCLISA ESCENA","generic":"ISATUXIMAB-IRFC","submissionType":"ORIG","submissionNumber":"1","classCode":"TYPE 3","classDescription":"Type 3 - New Dosage Form","statusDate":"2026-07-09","drugIds":["isatuximab"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA209092","sponsor":"NOVARTIS","brand":"KISQALI","generic":"RIBOCICLIB","submissionType":"SUPPL","submissionNumber":"27","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-01","drugIds":["ribociclib"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA210203","sponsor":"HETERO LABS LTD V","brand":"CAPECITABINE","generic":"CAPECITABINE","submissionType":"SUPPL","submissionNumber":"7","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-01","drugIds":["capecitabine-temozolomide","capecitabine"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA209935","sponsor":"NOVARTIS","brand":"KISQALI FEMARA CO-PACK (COPACKAGED)","generic":"LETROZOLE / RIBOCICLIB SUCCINATE","submissionType":"SUPPL","submissionNumber":"33","classCode":"EFFICACY","classDescription":"Efficacy","statusDate":"2026-07-01","drugIds":["ribociclib","letrozole"],"firstSeen":"2026-09-09"},{"applicationNumber":"ANDA211724","sponsor":"SOMERSET THERAPS LLC","brand":"CAPECITABINE","generic":"CAPECITABINE","submissionType":"SUPPL","submissionNumber":"6","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-07-01","drugIds":["capecitabine-temozolomide","capecitabine"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA215309","sponsor":"INCYTE CORP","brand":"OPZELURA","generic":"RUXOLITINIB","submissionType":"SUPPL","submissionNumber":"9","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-06-30","drugIds":["ruxolitinib"],"firstSeen":"2026-09-09"},{"applicationNumber":"NDA017962","sponsor":"ESJAY PHARMA","brand":"PARLODEL","generic":"BROMOCRIPTINE MESYLATE","submissionType":"SUPPL","submissionNumber":"89","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-06-30","drugIds":["bromocriptine"],"firstSeen":"2026-09-23"},{"applicationNumber":"NDA017962","sponsor":"ESJAY PHARMA","brand":"PARLODEL","generic":"BROMOCRIPTINE MESYLATE","submissionType":"SUPPL","submissionNumber":"80","classCode":"LABELING","classDescription":"Labeling","statusDate":"2026-06-30","drugIds":["bromocriptine"],"firstSeen":"2026-09-23"},{"applicationNumber":"ANDA219464","sponsor":"PHARMAZONE","brand":"EVEROLIMUS","generic":"EVEROLIMUS","submissionType":"ORIG","submissionNumber":"1","classCode":"UNKNOWN","statusDate":"2026-06-30","drugIds":["everolimus"],"firstSeen":"2026-09-09"}],"notInCorpus":[],"errors":[]}